Etravirine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 812 publications
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study.
Journal: The Journal of antimicrobial chemotherapy
Published: May 15, 2026
Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells.
Journal: Cells
Published: April 25, 2026
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios.
Journal: Viruses
Published: April 23, 2026
Deep learning-based prediction of drug-target interactions between antiviral drugs and SARS-CoV-2 proteins using an image-based representation approach.
Journal: Computational biology and chemistry
Published: April 21, 2026
Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.
Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026
Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens.
Journal: Pharmaceutics
Published: March 02, 2026
Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China
Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Published: March 01, 2026
Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective.
Journal: International journal of clinical pharmacy
Published: February 11, 2026
Outcomes for persons with triple-class resistant HIV and a history of virologic failure.
Journal: International journal of antimicrobial agents
Published: February 03, 2026
Correction: Ly et al. Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation Against Ovarian Cancer Metastasis. Int. J. Mol. Sci. 2022, 23, 944.
Journal: International journal of molecular sciences
Published: January 31, 2026
Cyclization-Inspired Structural Optimization: Designing Potent Non-nucleoside Reverse Transcriptase Inhibitors with Enhanced Safety and Selectivity.
Journal: Journal of medicinal chemistry
Published: January 09, 2026
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database.
Journal: The Journal of antimicrobial chemotherapy
Published: August 28, 2025
Last Updated: 09/26/2026